CliffBio
biologic

Rystiggo

rozanolixizumab-noli

Loss of exclusivityJune 2036projected — 12-year biologic exclusivity estimate
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameRystiggo
Active ingredientrozanolixizumab-noli
Strength840MG/6ML (140MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from UCB

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rystiggo patent cliff — loss of exclusivity June 2036 | CliffBio